Skip to content

The impact of the timing of combined use of GnRHa and GH on height gain in adolescents with advanced bone age and short stature

The impact of the timing of combined use of GnRHa and GH on height gain in adolescents with advanced bone age and short stature

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091737
Enrollment
Unknown
Registered
2024-11-01
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent large bone age short stature

Interventions

Group A: Starting GnRHa combined with growth hormone:None
Group B: Initial monotherapy with GnRHa, followed by the addition of growth hormone when the growth rate decreases:None

Sponsors

Yiwu Maternity and Children Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1. Initial treatment age: girls CA > 8 years, boys > 9 years, Tanner (stage II-III); 2. Bone age less than 13 years (girls) or less than 14 years (boys); 3. Legal guardians and the individual agree to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: If any of the following criteria are met, the individual must be excluded from this study: 1. Abnormal liver or kidney function. 2. History of hepatitis B or C, or known active hepatitis B or C. 3. Currently diagnosed or previously diagnosed with malignant tumors; 4. Confirmed to have other types of growth and development abnormalities, such as idiopathic short stature, Turner syndrome, Noonan syndrome, Laron syndrome, growth hormone receptor deficiency, small for gestational age with short stature, growth and development delay due to malnutrition, growth and development delay due to hypothyroidism, etc.; 5. Congenital skeletal developmental abnormalities or scoliosis (scoliosis angle =15 degrees, or moderate to severe scoliosis requiring treatment), limping; 6. Diagnosed with diabetes, or fasting blood glucose =126mg/dL (7.0mmol/L) or glycated hemoglobin (HbA1c) =6.5% at screening; 7. Participated in any other clinical study within 3 months prior to screening and has received drug or non-drug interventions; 8. Other conditions that the investigator deems unsuitable for inclusion in this clinical study.

Design outcomes

Secondary

MeasureTime frame
?GV;?Ht SDS;Adverse reaction;

Primary

MeasureTime frame
?PAH;

Countries

China

Contacts

Public ContactCAO XUYING

Yiwu Maternity and Children Hospital

13735619991@139.com+86 137 3561 9991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026